BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

Item

http://www.wikidata.org/entity/Q39156389

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

@en

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

@nl

type

Item

label

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

@en

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

@nl

prefLabel

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

@en

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

@nl

P1476

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

@en

P2093

Andreas Boehle

http://www.w3.org/2001/XMLSchema#string

Ashish M Kamat

http://www.w3.org/2001/XMLSchema#string

Debasish Sundi

http://www.w3.org/2001/XMLSchema#string

Donald Lamm

http://www.w3.org/2001/XMLSchema#string

J Alfred Witjes

http://www.w3.org/2001/XMLSchema#string

Joan Palou

http://www.w3.org/2001/XMLSchema#string

Marc Colombel

http://www.w3.org/2001/XMLSchema#string

Mark Soloway

http://www.w3.org/2001/XMLSchema#string

Maurizio Brausi

http://www.w3.org/2001/XMLSchema#string

Raj Persad

http://www.w3.org/2001/XMLSchema#string

P2860

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Thermosensitive hydrogels composed of hyaluronic acid and gelatin as carriers for the intravesical administration of cisplatin.

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer.

P2888

nrurol.2017.16

P304

244-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2017.16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28248951

http://www.w3.org/2001/XMLSchema#string